Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INFI

Infinity Pharmaceuticals (INFI) Stock Price, News & Analysis

Infinity Pharmaceuticals logo

About Infinity Pharmaceuticals Stock (NASDAQ:INFI)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$0.01
$0.13
52-Week Range
N/A
Volume
2.48 million shs
Average Volume
2.58 million shs
Market Capitalization
$726,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Remove Ads
Receive INFI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Infinity Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INFI Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

INFI Stock Analysis - Frequently Asked Questions

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) issued its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02. The biotechnology company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.45 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Infinity Pharmaceuticals investors own include Digital Turbine (APPS), ChargePoint (CHPT), CrowdStrike (CRWD), Vuzix (VUZI) and Sangamo Therapeutics (SGMO).

Company Calendar

Last Earnings
11/02/2021
Today
4/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INFI
Employees
30
Year Founded
2000

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,370,000.00
Net Margins
-1,593.93%
Pretax Margin
-1,593.93%

Debt

Sales & Book Value

Annual Sales
$2.59 million
Price / Cash Flow
N/A
Book Value
($0.21) per share
Price / Book
N/A

Miscellaneous

Free Float
81,857,000
Market Cap
$726,000.00
Optionable
Optionable
Beta
1.63

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:INFI) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners